ILD Source: Virtual Congress 2020 – Impact in children and in adults with premorbid respiratory disease (acute and long-term) Year: 2020
Coexistent COPD and ILD Source: Eur Respir Monogr 2015; 69: 109-120 Year: 2015
Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002
Interstitial lung disease in CVID (GLILD): clinical presentation and comparison to CVID without ILD Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019
Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM) Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003
Pathogenesis of ILD Source: ERS Course 2016 Year: 2016
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Pulmonary fibrosis and ILD Source: Research Seminar 2013 - Optimising models for human lung diseases and drug development Year: 2013
Delay in diagnosis of interstitial lung diseases (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007
Defining progression in non-IPF ILD Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021
Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001
Clinical case on ILD: a pulmonary case with many faces: not only interstitium Source: Annual Congress 2007 - Clinical Grand Round: an interactive session Year: 2007
COVID-19: Current Challenges in ILD Source: ERS webinar 2020: COVID-19: Current Challenges in ILD Year: 2020
Endothelin-1 in the exhaled breath condensate of patients with non-specific interstitial pneumonia (NSIP) and of patients with fibrosing alveolitis associated with systemic sclerosis (FASSc) Source: Eur Respir J 2002; 20: Suppl. 38, 226s Year: 2002
Fibrosing alveolitis in rheumatoid arthritis (FARA):a survival comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003
ProSP-B as a possible biomarker in idiopathic interstitial pneumonias (ILD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006
Interstitial lung diseases associated with amyopathic dermatomyositis Source: Eur Respir J 2006; 28: 1005-1012 Year: 2006
CT features of fibrosing alveolitis in rheumatoid arthritis (FARA): a comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003